<DOC>
	<DOC>NCT01153659</DOC>
	<brief_summary>This will be a randomized, open-label, single-center, 3-way crossover study in healthy subjects who are confirmed to be Helicobacter pylori (H. pylori)-negative. The study will consist of 3 study periods separated by a washout period of at least 7 days. Subjects will receive study drugs once daily for 5 days. Barring any safety concerns, subjects will be discharged from the study on Day 6 of Period 3 after completion of discharge procedures.</brief_summary>
	<brief_title>A Study to Evaluate the Effect on 24-hour, Intragastric pH of RAB ER 50-mg Capsules Compared With Esomeprazole (Nexium) 40 mg Capsules and Rabeprazole (Aciphex) 20-mg Tablets</brief_title>
	<detailed_description />
	<mesh_term>Rabeprazole</mesh_term>
	<mesh_term>Esomeprazole</mesh_term>
	<criteria>Key inclusion: Healthy male and female subjects, including women of childbearing potential, aged 18 to 55 years, inclusive Subjects who are able to tolerate the insertion and placement of a pH probe on 2 occasions per study period (Day 1 and Day 5) Key Exclusion: Subjects who are H. pyloripositive Subjects who have a history of any gastrointestinal disorder or surgery likely to influence drug absorption (e.g., history of gastric resection) Known hypersensitivity to rabeprazole, esomeprazole, or related compounds or any ingredient in the formulations Other standard clinical pharmacology exclusion criteria for healthy volunteers</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>rabeprazole</keyword>
	<keyword>esomeprazole</keyword>
	<keyword>h. pylori-negative</keyword>
	<keyword>nocturnal acid breakthrough</keyword>
	<keyword>intragastric pH, PK/PD</keyword>
	<keyword>effect on gastric pH in healthy, H. pylori-Negative subjects</keyword>
</DOC>